Comparative Pharmacology
Head-to-head clinical analysis: Q PAM versus TERAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: Q PAM versus TERAZOSIN HYDROCHLORIDE.
Q-PAM vs TERAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
100 mg orally twice daily
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker